108 related articles for article (PubMed ID: 8305629)
1. Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations.
Kiriyama A; Mimoto T; Kisanuki S; Kiso Y; Takada K
Biopharm Drug Dispos; 1993 Nov; 14(8):697-707. PubMed ID: 8305629
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNI-174, in rats after intravenous and intraduodenal administrations.
Kiriyama A; Mimoto T; Kiso Y; Takada K
Biopharm Drug Dispos; 1993 Apr; 14(3):199-207. PubMed ID: 8490108
[TBL] [Abstract][Full Text] [Related]
3. Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-1 protease inhibitor, KNI-272, in rats after intravenous administration.
Kiriyama A; Fujita K; Takemura S; Kuramoto H; Kiso Y; Takada K
Biopharm Drug Dispos; 1994 Oct; 15(7):617-26. PubMed ID: 7849237
[TBL] [Abstract][Full Text] [Related]
4. Absorption of new HIV-1 protease inhibitor, KNI-272, after intraduodenal and intragastric administrations to rats: effect of solvent.
Sugahara M; Kiriyama A; Hamada Y; Kiso Y; Takada K
Biopharm Drug Dispos; 1995 May; 16(4):269-77. PubMed ID: 7548776
[TBL] [Abstract][Full Text] [Related]
5. The bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogs.
Kiriyama A; Sugahara M; Yoshikawa Y; Kiso Y; Takada K
Biopharm Drug Dispos; 1996 Mar; 17(2):125-34. PubMed ID: 8907719
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing.
Mueller BU; Anderson BD; Farley MQ; Murphy R; Zuckerman J; Jarosinski P; Godwin K; McCully CL; Mitsuya H; Pizzo PA; Balis FM
Antimicrob Agents Chemother; 1998 Jul; 42(7):1815-8. PubMed ID: 9661027
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor.
Kiriyama A; Nishiura T; Yamaji H; Takada K
Biopharm Drug Dispos; 1999 May; 20(4):199-205. PubMed ID: 10440795
[TBL] [Abstract][Full Text] [Related]
8. Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes.
Kiriyama A; Nishiura T; Yamaji H; Takada K
Antimicrob Agents Chemother; 1999 Mar; 43(3):549-56. PubMed ID: 10049266
[TBL] [Abstract][Full Text] [Related]
9. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage.
Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y
J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064
[TBL] [Abstract][Full Text] [Related]
10. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
Kiriyama A; Nishiura T; Ishino M; Yamamoto Y; Ogita I; Kiso Y; Takada K
Biopharm Drug Dispos; 1996 Dec; 17(9):739-51. PubMed ID: 8968527
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationship of orally potent tripeptide-based HIV protease inhibitors containing hydroxymethylcarbonyl isostere.
Mimoto T; Hattori N; Takaku H; Kisanuki S; Fukazawa T; Terashima K; Kato R; Nojima S; Misawa S; Ueno T; Imai J; Enomoto H; Tanaka S; Sakikawa H; Shintani M; Hayashi H; Kiso Y
Chem Pharm Bull (Tokyo); 2000 Sep; 48(9):1310-26. PubMed ID: 10993230
[TBL] [Abstract][Full Text] [Related]
12. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins.
Kageyama S; Anderson BD; Hoesterey BL; Hayashi H; Kiso Y; Flora KP; Mitsuya H
Antimicrob Agents Chemother; 1994 May; 38(5):1107-11. PubMed ID: 8067746
[TBL] [Abstract][Full Text] [Related]
13. Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine.
Mimoto T; Imai J; Kisanuki S; Enomoto H; Hattori N; Akaji K; Kiso Y
Chem Pharm Bull (Tokyo); 1992 Aug; 40(8):2251-3. PubMed ID: 1423795
[TBL] [Abstract][Full Text] [Related]
14. A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection.
Humphrey RW; Wyvill KM; Nguyen BY; Shay LE; Kohler DR; Steinberg SM; Ueno T; Fukasawa T; Shintani M; Hayashi H; Mitsuya H; Yarchoan R
Antiviral Res; 1999 Feb; 41(1):21-33. PubMed ID: 10321576
[TBL] [Abstract][Full Text] [Related]
15. Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages.
Davis DA; Read-Connole E; Pearson K; Fales HM; Newcomb FM; Moskovitz J; Yarchoan R
Antimicrob Agents Chemother; 2002 Feb; 46(2):402-8. PubMed ID: 11796349
[TBL] [Abstract][Full Text] [Related]
16. KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic.
Mimoto T; Imai J; Tanaka S; Hattori N; Kisanuki S; Akaji K; Kiso Y
Chem Pharm Bull (Tokyo); 1991 Nov; 39(11):3088-90. PubMed ID: 1799953
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of human immunodeficiency virus protease inhibitor, nelfinavir, in poloxamer 407-induced hyperlipidemic model rats.
Sugioka N; Haraya K; Maeda Y; Fukushima K; Takada K
Biol Pharm Bull; 2009 Feb; 32(2):269-75. PubMed ID: 19182388
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of HIV protease inhibitor DMP 323 in rats and dogs.
Grubb MF; Wong YN; Burcham DL; Saxton PL; Quon CY; Huang SM
Drug Metab Dispos; 1994; 22(5):709-12. PubMed ID: 7835221
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of FK-506, a novel immunosuppressant, after intravenous and oral administrations to rats.
Takada K; Usuda H; Oh-Hashi M; Yoshikawa H; Muranishi S; Tanaka H
J Pharmacobiodyn; 1991 Jan; 14(1):34-42. PubMed ID: 1713626
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs.
Wong YN; Burcham DL; Saxton PL; Erickson-Viitanen S; Grubb MF; Quon CY; Huang SM
Biopharm Drug Dispos; 1994 Oct; 15(7):535-44. PubMed ID: 7849230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
